CROs/Service Providers

Survey: CRO oversight is a challenge for life science companies

Friday, November 18, 2016

Comprehend recently released a survey of over 100 Clinical Operations leaders from some of the most innovative, high-growth and demanding life sciences companies. The survey provides clear consensus on their goals, challenges and best practices for CRO oversight. It provides program, study and vendor oversight teams insights into how their peers are approaching this initiative. The biggest takeaway? Clinical Intelligence provides the CRO oversight and collaboration needed to deliver speed to quality results. 

[Read More]

Almac Group adds 312 jobs

Tuesday, November 15, 2016

Almac Group, a global contract pharmaceutical development and manufacturing organization, announced plans to expand its operations in Europe and North America, increasing its global headcount to reach 5,000 by 2017.

[Read More]

Bionical acquires Global CRO Emas Pharma

Monday, November 14, 2016

Bionical, the integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry, has announced the strategic acquisition of Emas Pharma, a global CRO. Emas, which provides pharmaceutical development and clinical research services to biotech, medical device and specialized pharmaceutical companies worldwide, will join Bionical’s existing fast growing clinical services business. Financials were not disclosed.

[Read More]

INC Research to manage Leukemia & Lymphoma Society umbrella trial

Friday, November 11, 2016

INC Research, a global phase I to IV CRO, has announced its involvement in The Leukemia & Lymphoma Society’s (LLS) recently-launched precision medicine Master Trial to treat acute myeloid leukemia (AML). The Beat AML Master Trial is breaking ground in a number of areas, including the first time a nonprofit organization is working with multiple biotech and pharma sponsors and other key collaborators to professionally operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML.

[Read More]

CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

Wednesday, November 9, 2016

CiToxLAB, a preclinical CROs, has announced the acquisition of AccelLAB, a Canadian CRO specialized in the preclinical assessment of new medical devices. Through this acquisition, CiToxLAB Group reinforces its position in the non-clinical CRO arena and enlarges its services portfolio to medical devices, a fast growing area which offers large synergies with drug development, the CiToxLAB’s core business.

[Read More]

Envigo launches hepatotoxicity testing for drug development de-risking program

Monday, November 7, 2016

Envigo has launched an integrated program of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI)—one of the major causes of drugs being withdrawn from the market. Since 1980, over 30 drugs have been withdrawn because of hepatotoxicity with many others having severe restrictions placed upon their use. As a consequence, and to help minimize any risks to patients taking their medicines, the pharma industry is concerned not to progress compounds that show any potential DILI liability.

[Read More]